Characterization of changes in FibroTest values during treatment with tenofovir alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) in patients with CHB

Izumi, NamikiTsang, Owen Tak YinAhn, Sang HoonAngus, Peter W.Flaherty, John F.Kim, KyungpilGaggar, AnujSuri, VithikaSubramanian, ManiCooper, CurtisHann, Hie-WonAcharya, Subrat K.2023-05-172023-05-172016-10Izumi, N, vd. (2016). "Characterization of changes in FibroTest values during treatment with tenofovir alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) in patients with CHB". Hepatology, 64(Supplement 1), 941A-942A.0270-91391527-3350https://www.natap.org/2016/AASLD/AASLD_92.htmhttp://hdl.handle.net/11452/32689Bu çalışma, 11-15 Kasım 2016 tarihlerinde Boston[Amerika Birleşik Devletleri]’ da düzenlenen 67. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology & hepatologyCharacterization of changes in FibroTest values during treatment with tenofovir alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) in patients with CHBMeeting Abstract000385493804264941A942A64Supplement 1Gastroenterology & hepatology